LGBTQ+ social network company Grindr Inc (NYSE: GRND) announced on Monday that it has collaborated with Equality Movement and MPOWER to launch at-home HIV self-test kits for Grindr users in Georgia and Ireland.
This initiative, marking European testing week, extends Grindr's commitment to overcoming barriers to HIV testing, particularly for users facing challenges like rural residence or privacy concerns. The partnerships allow Grindr users in these countries to order free at-home HIV self-test kits directly through the app, offering a convenient and discreet option for health protection.
Grindr's history of promoting Equality Movement and MPOWER's home self-testing programs underscores its dedication to community-level interventions and judgment-free resources. This expansion follows Grindr's successful Together TakeMeHome program, in collaboration with Building Healthy Online Communities and Emory University, which distributed over 232,262 test kits within its first six months, emphasizing Grindr's commitment to similar global initiatives.
With over 13 million monthly active users globally, Grindr remains focused on fostering connections, self-expression and community support.
Benuvia Operations signs licensing and supply agreements with Medra Brasil Medicamentos
Castle Biosciences to present data on Melanoma tests at ASDP Annual Meeting
Alchemy partners with PatchRx to improve HIV medication adherence
Gilead expands global access to lenacapavir for HIV prevention
Alume Biosciences names new chief commercial officer
genedrive plc secures initial UK order for Genedrive CYP2C19-ID Kit
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Gilead study suggests lenacapavir superior to Truvada
Oxford BioDynamics announces opening of clinical testing facility in UK for prostate screening test
Micron Biomedical names new scientific advisor to CEO
China accepts GSK's Shingrix application for at-risk adults
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Allurion's Gastric Balloon introduced at Somerset NHS Foundation Trust for pre-surgical weight loss
Takeda's HYQVIA gains FDA approval for CIDP maintenance therapy